MedTrace Logo

2-cohort Study of Adult Patients With Severe Hemophilia A in Greece

NCT02319070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2018-06-20

No results posted yet for this study

Summary

This study is a prospective, single center, observational, 2-cohort study of adult patients with severe Hemophilia A. There is no randomization procedure and all patients will be treated as per usual clinical practice. Patients will be followed up for 18 months after enrolment.

Conditions

Interventions

OTHER

Survey

Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine

OTHER

Survey

Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-13
Primary Completion
2017-05-28
Completion
2018-02-28

Countries

  • Greece

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319070 on ClinicalTrials.gov